The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
The week-long campaign received a record 17.691 pledges
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Subscribe To Our Newsletter & Stay Updated
